Delivery Order HHSN261201200032I-HHSN26100002

This is a $364,672.04 federal contract awarded by the National Cancer Institute (NCI) to Mayo Clinic, a large non-profit academic medical center, to conduct a Phase I double-blind, placebo-controlled trial of 0.3mg linaclotide delayed-release (DR1) to demonstrate colorectal bioactivity in healthy volunteers. The contract is a delivery order under the NCI's Cancer Prevention Agent Development Program: Early Phase Clinical Research program and does not have a set-aside designation. Mayo Clinic...

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $248,273.25 cost-no-fee delivery order contract to Mayo Clinic, a large non-profit academic medical center, to conduct a phase 0 trial of the drug linaclotide to demonstrate its colorectal bioactivity in healthy volunteers. This contract, which does not have a set-aside designation, was awarded on September 24, 2012 with a completion date of September 23, 2015. Mayo Clinic has a...

This is a definitive contract awarded by the National Cancer Institute, a civilian agency, to the Preventive Medicine Institute for a Phase II clinical trial of celecoxib (or NSAID) for the prevention of sporadic colorectal adenomas. The contract has a ceiling value of $38,582,232.00 and a completion date of March 30, 2010. It is a cost-no-fee contract and was not set aside for a specific type of business. The contract provides funding for clinical research to evaluate the effectiveness of...

This federal contract award from the National Cancer Institute (NCI), part of the Department of Health and Human Services, is for a clinical research study to evaluate the efficacy of intermittent dosing of aspirin for colorectal cancer prevention. The prime contractor is Northwestern University, a private research university, which has been awarded this $1,057,268.80 task order under the NCI's "Cancer Prevention Agent Development Program 2012-2017" indefinite delivery contract. The...

This is a delivery order award under the National Cancer Institute's PREVENT Preclinical Drug Development Program, a $149,995,000 indefinite-delivery, indefinite-quantity (IDIQ) contract. The award, valued at $878,817.03, is for a task order titled "Preventing Colorectal Cancer Using TRAIL-Inducing ONC201 Alone or in Combination with NSAID." The prime contractor is the University of Oklahoma Health Sciences Center, a state-funded public research university with significant federal...

This is a firm fixed-price delivery order contract awarded by the Department of Health and Human Services, National Institutes of Health, National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract, valued at $979,494.00, is for research to determine dosing regimens of the drug erlotinib in combination with sulindac for the prevention of colorectal cancer while reducing agent toxicity. The research is part of the...

This federal contract award was made by the National Cancer Institute, a civilian agency, to the University of Alabama at Birmingham (UAB) under the PREVENT Preclinical Drug Development Program (PREVENT). The $1,498,585.64 task order is for the research and development of a novel EPA analogue TP-252 and naproxen for colorectal cancer prevention in familial adenomatous polyposis (FAP) and Lynch syndrome models. The contract has no set-aside designation. UAB has performed numerous federal...

The University of Texas M.D. Anderson Cancer Center has been awarded a $854,290 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ vehicle held by the National Cancer Institute. Under this contract, M.D. Anderson will conduct optimization of dosing regimens of sulindac in combination with erlotinib for small intestinal and colon cancer prevention. The work directly supports the National Cancer Institute's PREVENT preclinical drug...

This is a delivery order issued under the National Cancer Institute's PREVENT Cancer Program (PREVENT) contract. The order, valued at $834,263.00, was awarded to the University of Oklahoma Health Sciences Center (OUHSC) to determine the potential clinical usefulness of aspirin and naproxen (another NSAID) for prostate cancer prevention using preclinical models. The University of Colorado-Denver is a subcontractor supporting this research. The award has a period of performance from July 2016 to...

This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to The Institute for Cancer Research (ICR), a non-profit subsidiary of Temple University. The $1,237,620.00 task order is for the development of "Next Generation GP130/IL-6/STAT3 Inhibitors for the Prevention of Colitis-Associated Colorectal Cancer" under the PREVENT Preclinical Drug Development Program (PREVENT), a $149,995,000 multiple-award Indefinite Delivery Contract (IDC) held by Temple...